Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.

Who May Qualify: - Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm. - Over 18 years old. - Signed willing to sign a consent form - If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period. Who Should NOT Join This Trial: - Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection. - Any other previous or present pathology having an impact on motor function. - Recent surgery or trauma (less than 6 months) in the upper or lower limbs. - Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion. - Patients participating in an interventional clinical trial. Always talk to your doctor about whether this trial is right for you.